The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Dec. 12, 2023

Filed:

May. 06, 2020
Applicant:

Gracell Biotechnologies (Shanghai) Co., Ltd., Shanghai, CN;

Inventors:

Hua Zhang, Shanghai, CN;

Huan Shi, Shanghai, CN;

Lianjun Shen, Shanghai, CN;

Wei Cao, Shanghai, CN;

Liping Liu, Shanghai, CN;

Attorney:
Primary Examiner:
Int. Cl.
CPC ...
C07K 16/28 (2006.01); A61P 35/00 (2006.01); A61K 35/17 (2015.01); C07K 14/725 (2006.01); C07K 14/71 (2006.01); A61K 38/00 (2006.01); A61K 39/00 (2006.01);
U.S. Cl.
CPC ...
C07K 16/2878 (2013.01); A61K 35/17 (2013.01); A61P 35/00 (2018.01); C07K 14/7051 (2013.01); C07K 14/71 (2013.01); C07K 16/2803 (2013.01); A61K 38/00 (2013.01); A61K 2039/505 (2013.01); C07K 2317/31 (2013.01); C07K 2317/53 (2013.01); C07K 2317/622 (2013.01); C07K 2317/76 (2013.01); C07K 2319/02 (2013.01); C07K 2319/03 (2013.01); C07K 2319/30 (2013.01); C07K 2319/33 (2013.01);
Abstract

The present invention provides an engineered immune cell targeting BCMA and use thereof. In particular, the present invention provides a CAR specifically targeting BCMA, the CAR comprising an antigen-binding domain which is an S-derived scFv, an antibody heavy chain variable region as shown in SEQ ID NO: 9 and an antibody light chain variable region as shown in SEQ ID NO: 10. The present invention also provides a CAR-T cell comprising the CAR, a double CAR- and CAR-T cell comprising the S-derived scFv, and related use thereof. Compared to CAR-T cells constructed using other scFvs, the constructed CAR-T cell of the present invention has a better killing effect and tumor elimination capability.


Find Patent Forward Citations

Loading…